Drug Database · Clinicians

Paroxetine

Brands (3) Sempravyl, Seroxat, Xet 20Show all

US brand (reference label): PAXIL; not a Philippine-registered brand.

Antidepressant (selective serotonin reuptake inhibitor); Anti-depressant PH FDA category

Rx · Prescription drug4 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e, version date September 29, 2026 (PAXIL · Apotex Corp). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Major depressive disorder (MDD) in adults Obsessive compulsive disorder (OCD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Generalized anxiety disorder (GAD) in adults Posttraumatic…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE PAXIL is indicated in adults for the treatment of: Major depressive disorder (MDD) in adults Obsessive compulsive disorder (OCD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Generalized anxiety disorder (GAD) in adults Posttraumatic stress disorder (PTSD) in adults PAXIL is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of (1): Major depressive disorder (MDD) in adults Obsessive compulsive disorder (OCD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Generalized anxiety disorder (GAD) in adults Posttraumatic stress disorder (PTSD) in adults

Contraindications

4 CONTRAINDICATIONS PAXIL is contraindicated in patients: Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2) and Drug Interactions (7)]. Who receive drugs that can prolong QTc interval and are also CYP450 2D6 substrates [see Drug Interactions (7) and Warnings and Precautions (5.3)] With known hypersensitivity to paroxetine or any of the inactive ingredients in PAXIL.

Hypersensitivity reactions have included anaphylaxis, angioedema, and Stevens- Johnson syndrome [see Adverse Reactions (6.1), (6.2)]. PAXIL is contraindicated in patients: Taking, or within 14 days of stopping monoamine oxidase inhibitors (MAOIs) (4, 5.2, 7) Who receive drugs that can prolong QTc interval and are also CYP2D6 substrates (4, 5.3, 7) Known hypersensitivity to paroxetine or to any of the inactive ingredients in PAXIL.

(4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Prior to initiating treatment with PAXIL, screen patients for a personal or family history of bipolar disorder, mania, or hypomania (2.1, 5.6)
  • Administer PAXIL as a once daily dose in the morning, with or without food. Administer the tablets or the oral suspension. Shake oral suspension well before administration (2. 2) · Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD in the table below. If inadequate response to starting dosage, increase the dosage by 10 mg/day weekly intervals (e.g., if the starting dosage is 20 mg/day increase the dosage the next week to 30 mg/day) to the maximum dosage: (3) Indication Starting Daily Dosage Maximum Daily Dosage MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg Recommended starting dosage for SAD is 20 mg once daily. After 1-2 weeks, may increase the PAXIL dosage by 10 mg/day in weekly intervals (e.g., after 1-2 weeks may increase the PAXIL dosage from 20 mg/day to 30 mg/day) up to a maximum dosage of 60 mg once daily (2.4)
  • Recommended starting dosage for GAD is 10 mg once daily. After one week, increase the dosage to 20 mg once daily. In patients with an inadequate response, may increase the PAXIL dosage by 10 mg/day at weekly intervals (e.g., after 1 week may increase the PAXIL dosage from 20 mg/day to 30 mg/day), up to a maximum of 50 mg/day (2.5)
  • Geriatric patients, patients with severe …
2.1 Screen for Bipolar Disorder Prior to Starting

2.1 Screen for Bipolar Disorder Prior to Starting PAXIL Prior to initiating treatment with PAXIL, screen patients for a personal or family history of bipolar disorder, mania, or hypomania [see Warnings and Precautions (5.6)].

2.2 Important Administration Instructions

2.2 Important Administration Instructions Administer PAXIL as a once daily dose in the morning, with or without food [see Clinical Pharmacology (12.3)]. Administer the tablets or the oral suspension. Shake the oral suspension well before administration.

2.3 Recommended Dosage for MDD, OCD, PD, and PTSD

2.3 Recommended Dosage for MDD, OCD, PD, and PTSD The recommended starting dosages and maximum dosages of PAXIL in patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), panic disorder (PD), and posttraumatic stress disorder (PTSD) are presented in Table 1. In patients with an inadequate response, increase PAXIL dosage by 10 mg/day at intervals of at weekly intervals (e.g., if the starting dosage is 20 mg/day increase the dosage the next week to 30 mg/day), depending on tolerability, up to the maximum recommended dosage.

Table 1: Recommended Daily Dosage of PAXIL in Patients with MDD, OCD, PD, and PTSD Indication Starting Dosage Maximum Once Daily Dosage MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg

2.4 Recommended Dosage for SAD

2.4 Recommended Dosage for SAD The starting and recommended starting dosage of PAXIL in adult patients with social anxiety disorder (SAD) is 20 mg once daily. After 1-2 weeks, may increase the PAXIL dosage by 10 mg/day in weekly intervals (e.g., after 1-2 weeks may increase the PAXIL dosage from 20 mg/day to 30 mg/day) up to a maximum dosage of 60 mg once daily.

In clinical trials the effectiveness of PAXIL for the treatment of SAD was demonstrated in adult patients dosed in a range of 20 mg once daily to 60 mg once daily (after dosage titration). Available information does not suggest any additional benefit for a PAXIL dosage above 20 mg once daily for the treatment of SAD [see Clinical Studies (14.4)].

2.5 Recommended Dosage for GAD

2.5 Recommended Dosage for GAD The recommended starting PAXIL dosage in adult patients with generalized anxiety disorder (GAD) is 10 mg once daily. After one week, increase the PAXIL dosage to 20 mg once daily. In patients with an inadequate response, may increase the PAXIL dosage by 10 mg/day at weekly intervals (e.g., after 1 week may increase the PAXIL dosage from 20 mg/day to 30 mg/day), depending on tolerability, up to a maximum of 50 mg/day.

In clinical trials the effectiveness of PAXIL in the treatment GAD was demonstrated in patients dosed in a range of 20 mg to 50 mg once daily (after titration). There is not sufficient evidence to suggest a greater benefit with a PAXIL dosage higher than 20 mg once daily [see Clinical Studies (14.5)].

2.6 Recommended Dosage in Geriatric Patients

2.6 Recommended Dosage in Geriatric Patients, Patients with Severe Renal Impairment, and Patients with Severe Hepatic Impairment The recommended starting PAXIL dosage is 10 mg/day in geriatric patients, patients with severe renal impairment, and patients with severe hepatic impairment. The maximum recommended dosage in these patients is 40 mg/day.

2.7 Switching Patients to or From a Monoamine Oxidase Inhibitor

2.7 Switching Patients to or From a Monoamine Oxidase Inhibitor At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOI) and initiation of PAXIL. In addition, at least 14 days must elapse after stopping PAXIL before starting an MAOI antidepressant [see Contraindications (4), Warnings and Precautions (5.2)].

2.8 Discontinuation

2.8 Discontinuation of PAXIL Treatment When discontinuing PAXIL treatment, gradually reduce the dosage rather than stopping PAXIL abruptly whenever possible [see Warnings and Precautions (5.7) and Drug Abuse and Dependence (9.3)].

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, use in specific populations)

2.6 Recommended Dosage in Geriatric Patients, Patients with Severe Renal Impairment, and Patients with Severe Hepatic Impairment The recommended starting PAXIL dosage is 10 mg/day in geriatric patients, patients with severe renal impairment, and patients with severe hepatic impairment. The maximum recommended dosage in these patients is 40 mg/day.

8.6 Renal Impairment Compared to those without renal impairment (RI), paroxetine plasma concentrations in patients with RI were increased, which may increase the risk of paroxetine-associated adverse reactions. Paroxetine plasma concentrations were higher in patients with greater degrees of RI. The recommended starting and maximum dosage of PAXIL is lower in patients with severe RI compared to those without RI [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. The recommended PAXIL dosage in patients with mild RI or moderate RI is the same as in those without RI.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment Compared to those without hepatic impairment (HI), paroxetine plasma concentrations in patients with severe hepatic impairment (HI) were increased, which may increase the risk of paroxetine-associated adverse reactions. The recommended starting and maximum dosage of PAXIL is lower in patients with severe HI compared to those without HI [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]. The recommended dosage in patients with mild or moderate HI is the same as in those without HI.

US FDA label

Administration

2.2 Important Administration Instructions Administer PAXIL as a once daily dose in the morning, with or without food [see Clinical Pharmacology ( 12.3 )]. Administer the tablets or the oral suspension. Shake the oral suspension well before administration.

US FDA label

Dosage forms

Philippines

  • Film-coated tablet: 20 mg
  • Tablet: 20 mg

Registered products in the Philippines

4 products registered with the Food and Drug Administration (FDA) Philippines list Paroxetine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products4
Philippine FDA-registered products for Paroxetine
Package insert
NoneParoxetine (as Hydrochloride)
20 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
UNILAB, Inc.Philippines
Trader: RITEMED PHILS., INC.
DRP-1517
Jul 14, 2029
SempravylParoxetine
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's)
RxVAT-exempt
Kusum Healthcare Pvt. Ltd.India
Kusum Healthcare Private Limited Branch Office
DR-XY49435
Jul 11, 2030
SeroxatParoxetine
20 mg TabletPVC/Aluminum/Paper Blister Pack x 10's (Box of 30's)
RxVAT-exempt
GlaxoSmithKline Pharmaceuticals S.A.Poland
Importer: GlaxoSmithKline Philippines, Inc.
DR-XY16055
Feb 16, 2027
Xet 20Paroxetine (as Hydrochloride)
20 mg Film-Coated TabletAlu-Alu Blister Pack x 10 Tablets (Box of 10's)
RxVAT-exempt
Zydus Lifesciences LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-7536
Feb 28, 2032

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Tablets: 10 mg yellow, functionally scored engraved on the front with “PAXIL” and on the back with “10”. 20 mg pink, functionally scored engraved on the front with “PAXIL” and on the back with “20”. 30 mg blue engraved on the front with “PAXIL” and on the back with “30”. 40 mg green engraved on the front with “PAXIL” and on the back with “40”. PAXIL oral suspension is available as: 10 mg/5 mL orange colored, orange flavored suspension in bottles containing 250 mL (not currently marketed).

Tablets: 10 mg, 20 mg, 30 mg, and 40 mg. (3) Oral suspension: 10 mg/5 mL (not currently marketed). (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Serotonin Syndrome:: Monitor all patients taking PAXIL for the emergence of serotonin syndrome.. If occurs, immediately discontinue PAXIL and serotonergic agents and initiate supportive measures. (5.2)
  • Embryofetal Toxicity: For women who intend to become pregnant or who are in their first trimester of pregnancy, PAXIL, should be initiated only after consideration of the other available treatment options (5.4, 8.1)
  • Increased Risk of Bleeding: For patients taking warfarin, carefully monitor the international normalized ratio when initiating, titrating, or discontinuing PAXIL (5.5)
  • Seizures: Use with caution in patients with seizure disorders. Discontinue PAXIL in any patient who develop a seizure (5.8)
  • Angle-Closure Glaucoma: Avoid use of PAXIL in patients with untreated anatomically narrow angles. (5.9)
  • Hyponatremia: In patients with symptomatic hyponatremia, discontinue PAXIL and institute appropriate medical intervention (5.10)
  • Sexual Dysfunction: Inquire about sexual function prior to initiation of PAXIL and to inquire specifically about changes in sexual function during PAXIL treatment (5.11)
5.1 Suicidal Thoughts and Behaviors in Pediatric Patients and Young Adults

5.1 Suicidal Thoughts and Behaviors in Pediatric Patients and Young Adults In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There were differences in absolute risk of suicidal thoughts and behaviors across the different uses, with the highest incidence in patients with MDD.

The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 2. Table 2: Risk Differences of the Number of Patients with Suicidal Thoughts and Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric 1 and Adult Patients Age Range Drug-Placebo Difference in Number of Patients with Suicidal Thoughts and Behaviors per 1,000 Patients Treated Increases Compared to Placebo <18 years old 14 additional cases 18-24 years old 5 additional cases Decreases Compared to Placebo 25-64 years old 1 fewer case ≥65 years old 6 fewer cases 1 PAXIL is not approved for use in pediatric patients.

It is unknown whether the risk of suicidal thoughts and behaviors in pediatric patients and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors.

Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider.

Consider changing the therapeutic regimen, including possibly discontinuing PAXIL, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

5.2 Serotonin Syndrome

5.2 Serotonin Syndrome Selective serotonin reuptake inhibitors (SSRIs), including PAXIL, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines and St.

John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications (4), Drug Interactions (7.1)]. Serotonin syndrome can also occur when PAXIL is used alone. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

The concomitant use of PAXIL with MAOIs is contraindicated. In addition, do not initiate PAXIL in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes of administration (such as orally or local tissue injection) or at lower doses.

If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking PAXIL discontinue PAXIL before initiating treatment with the MAOI [see Contraindications (4) and Drug Interactions (7)]. Monitor all patients taking PAXIL for the emergence of serotonin syndrome. Discontinue treatment with PAXIL and any concomitant serotonergic drug immediately if the above symptoms occur, and initiate supportive symptomatic treatment.

If concomitant use of PAXIL with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.

5.3 Drug Interactions Leading to QTc Interval Prolongation Cases

5.3 Drug Interactions Leading to QTc Interval Prolongation Cases of QTc interval prolongation have been reported with the use of paroxetine, although causal relationship with PAXIL has not been established. PAXIL is a strong CYP2D6 inhibitor. Concomitant use of PAXIL with CYP2D6 substrates that prolong the QTc interval can increase the concentration of those CYP2D6 substrates and may result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsade de pointes, other serious arrythmias, and sudden death.

The concomitant use of PAXIL is contraindicated with CYP2D6 substrates that prolong the QTc interval [see Drug Interactions (7) and Clinical Pharmacology (12.3)].

5.4 Embryofetal Toxicity

5.4 Embryofetal Toxicity PAXIL can cause fetal harm when administered to a pregnant woman. Based on meta-analyses of epidemiological studies, exposure to paroxetine in the first trimester of pregnancy is associated with a less than 2-fold increase in the rate of cardiovascular malformations among infants. For women who intend to become pregnant or who are in their first trimester of pregnancy, PAXIL, should be initiated only after consideration of the other available treatment options [see Use in Specific Populations (8.1)].

5.5 Increased Risk of Bleeding

5.5 Increased Risk of Bleeding Drugs that interfere with serotonin reuptake inhibition, including PAXIL, increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), other antiplatelet drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding.

Based on data from the published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Use in Specific Populations (8.1)]. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages.

Inform patients about the increased risk of bleeding associated with the concomitant use of PAXIL and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio when initiating, titrating, or discontinuing PAXIL.

5.6 Activation of Mania or Hypomania

5.6 Activation of Mania or Hypomania In patients with bipolar disorder, treating a depressive episode with PAXIL or another antidepressant may precipitate a mixed/manic episode. During controlled clinical trials of PAXIL for unipolar depression, hypomania or mania occurred in approximately 1% of PAXIL-treated patients compared to 1.1% of active-control and 0.3% of placebo-treated patients.

Prior to initiating treatment with PAXIL, screen patients for any personal or family history of bipolar disorder, mania, or hypomania.

5.7 Discontinuation Syndrome

5.7 Discontinuation Syndrome Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. During clinical trials of GAD and PTSD, gradual decreases in the daily PAXIL dosage by 10 mg/day at weekly intervals followed by 1 week at 20 mg/day was used before treatment was discontinued.

The following adverse reactions were reported at an incidence of 2% or greater for PAXIL and were at least twice that reported for placebo: abnormal dreams, paresthesia, and dizziness adverse reactions have been reported upon discontinuation of treatment with PAXIL in pediatric patients. The safety and effectiveness of PAXIL in pediatric patients have not been established [see Warnings and Precautions (5.1), Use in Specific Populations (8.4)].

When discontinuing PAXIL, a gradual reduction in dosage rather than abrupt cessation is recommended whenever possible [see Dosage and Administration (2.7)].

5.8 Seizures

5.8 Seizures PAXIL has not been systematically evaluated in patients with seizure disorders. Patients with history of seizures were excluded from clinical studies. During clinical studies, seizures occurred in 0.1% of patients treated with PAXIL. PAXIL should be prescribed with caution in patients with a seizure disorder.

Discontinue PAXIL in any patient who develops a seizure.

5.9 Angle-Closure Glaucoma

5.9 Angle-Closure Glaucoma The pupillary dilation that occurs following use of many antidepressant drugs including PAXIL may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Cases of angle-closure glaucoma associated with use of PAXIL have been reported.

Avoid use of antidepressants, including PAXIL in patients with untreated anatomically narrow angles.

5.10 Hyponatremia

5.10 Hyponatremia Hyponatremia may occur as a result of treatment with SSRIs, including PAXIL. Cases with serum sodium lower than 110 mmol/L have been reported. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls.

Signs and symptoms associated with more severe and/or acute hyponatremia cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations (8.5)].

In patients with symptomatic hyponatremia, discontinue PAXIL and institute appropriate medical intervention.

5.11 Sexual Dysfunction Use

5.11 Sexual Dysfunction Use of SSRIs, including PAXIL, may cause symptoms of sexual dysfunction [see Adverse Reactions (6.1)]. In male patients, SSRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SSRI use may result in decreased libido and delayed or absent orgasm.

Recommend prescribers inquire about sexual function prior to initiation of PAXIL and to inquire specifically about changes in sexual function during PAXIL treatment because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtain a detailed history (including timing of symptom onset) because sexual symptoms may have other causes, including the underlying psychiatric disorder.

Discuss potential management strategies to support patients in making informed decisions about treatment for sexual dysfunction.

5.12 Risk of Reduced of Efficacy of Tamoxifen

5.12 Risk of Reduced of Efficacy of Tamoxifen Some studies have shown that the efficacy of tamoxifen, as measured by breast cancer relapse and mortality, may be reduced with concomitant use of PAXIL as a result of paroxetine’s irreversible CYP2D6 inhibition and lower concentration of the active metabolite of tamoxifen [see Drug Interactions (7)]. One study suggested that the risk may increase with longer duration of concomitant use of PAXIL and tamoxifen.

However, other studies have failed to demonstrate such a risk. When tamoxifen is used for the treatment or prevention of breast cancer, prescribers should consider using an alternative antidepressant with little or no CYP2D6 inhibition rather than PAXIL.

5.13 Fracture Risk

5.13 Fracture Risk Epidemiological studies on fracture risk during exposure to some antidepressant drugs, including SSRIs, have reported an association between antidepressant drug treatment and fractures. There are multiple possible causes for this association, and it is unknown to what extent fracture risk is directly attributable to SSRI treatment.

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Table 9 presents clinically significant drug interactions with PAXIL. Table 9: Clinically Significant Drug Interactions with PAXIL Monoamine Oxidase Inhibitors Mechanism and Clinical Effect(s) The concomitant use of SSRIs, including PAXIL and monoamine oxidase inhibitors (MAOIs) increases the risk of serotonin syndrome.

Prevention or Management PAXIL is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Dosage and Administration (2.5) and Warnings and Precautions (5.2)]. CYP2D6 Substrates that Prolong the QTc Interval Mechanism and Clinical Effect(s) PAXIL is a strong CYP2D6 inhibitor.

Concomitant use of PAXIL with CYP2D6 substrates that prolong the QTc interval can increase the concentration of those CYP2D6 substrates and may result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation [see Warnings and Precautions (5.3)]. Prevention or Management PAXIL is contraindicated in patients taking drugs that can prolong QTc interval and are CYP2D6 substrates.

Other Serotonergic Drugs Mechanism and Clinical Effect(s) The concomitant use of PAXIL with serotonergic drugs increases the risk of serotonin syndrome. Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome with concomitant use of PAXIL and other serotonergic drugs. If serotonin syndrome occurs, immediately discontinue treatment with PAXIL and/or concomitant serotonergic drugs [see Warnings and Precautions (5.2)].

Drugs that Interfere with Hemostasis (antiplatelet drugs and anticoagulants) Mechanism and Clinical Effect(s) The concomitant use of an antiplatelet drug or anticoagulant with PAXIL may potentiate the risk of bleeding. Prevention or Management Inform patients of the increased risk of bleeding associated with the concomitant use of PAXIL and antiplatelet drugs or anticoagulants.

For patients taking warfarin, carefully monitor the international normalized ratio when initiating, titrating, or discontinuing PAXIL [see Warnings and Precautions (5.5)]. Drugs Highly Bound to Plasma Protein Mechanism and Clinical Effect(s) Paroxetine is highly bound to plasma protein. The concomitant use of PAXIL with another drug that is highly bound to plasma protein may increase free concentrations of paroxetine or other tightly-bound drugs in plasma.

Prevention or Management Monitor for adverse reactions and reduce dosage of PAXIL or other protein-bound drugs as warranted. CYP2D6 Substrates Mechanism and Clinical Effect(s) PAXIL is a strong CYP2D6 inhibitor [see Clinical Pharmacology (12.3)]. The concomitant use of PAXIL with a CYP2D6 substrate may increasethe exposure of the CYP2D6 substrate and increase the risk of CYP2D6 substrate-associated adverse reactions.

Prevention or Management With concomitant use with PAXIL, decrease the dosage of a CYP2D6 substrate if needed. Tamoxifen Mechanism and Clinical Effect(s) Concomitant use of tamoxifen with PAXIL may lead to reduced plasma concentrations of the active metabolite of tamoxifen (i.e., endoxifen) and reduced efficacy of tamoxifen Prevention or Management Consider use of an alternative antidepressant with little or no CYP2D6 inhibition [see Warnings and Precautions (5.11)].

Fosamprenavir/Ritonavir Mechanism and Clinical Effect(s) Concomitant use of fosamprenavir/ritonavir with PAXIL significantly decreased plasma levels of paroxetine. Prevention or Management Any PAXIL dosage modification should be guided by clinical effect (tolerability and efficacy). Drugs Highly Bound to Plasma Protein: Monitor for adverse reactions and reduce dosage of PAXIL or other protein-bound drugs (e.g., warfarin) as warranted.

(7) CYP2D6 Substrates: Reduce dosage of the CYP2D6 substrate if needed. (7) Concomitant use with Tamoxifen: Consider use of an alternative antidepressant with little or no CYP2D6 inhibition. (5.11, 7)

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

The metabolism of paroxetine is accomplished in part by CYP2D6.

Saturation of CYP2D6 at clinical doses appears to account for the nonlinearity of paroxetine kinetics with increasing dose and increasing duration of treatment.

The role of CYP2D6 in paroxetine metabolism increases the risk of drug interactions [see Drug Interactions ( 7 )] .

Pharmacokinetic characteristics of paroxetine has not been evaluated in subjects who are deficient in CYP2D6 (CYP2D6 poor metabolizers).

Impact of Paroxetine on the Pharmacokinetics of Co-Administered Drugs (log scale) Pimozide is a 3A4 moderate sensitive substrate and is a CYP2D6 substrate; desipramine is a 2D6 sensitive substrate; propranolol is a 2D6 moderate sensitive substrate, digoxin is P-gp substrate, and phenytoin is a 3A4 strong inhibitor.

Impact of Concomitantly Administered Drugs on the Pharmacokinetics of Paroxetine Cimetidine is a OCT2, MATE1, and MATE2-K inhibitor, phenobarbital is a 3A4 moderate inducer, phenytoin is a 3A4 strong inhibitor, digoxin is P-gp substrate, and diazepam is a 2C19 moderate sensitive substrate.

Theophylline: Reports of elevated theophylline levels associated with PAXIL treatment have been reported Drugs Metabolized by Cytochrome CYP3A4 : An in vivo interaction study involving the concomitant use of steady-state paroxetine and a substrate for CYP3A4, revealed no effect of paroxetine on pharmacokinetics of the CYP3A4 substrate.

In addition, in vitro studies have shown ketoconazole, a severe CYP3A4 inhibitor activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for CYP3A4, including triazolam and cyclosporine.

Adverse reactions

Adverse reactions (US label) US FDA label

The following adverse reactions are included in more detail in other sections of the prescribing information: Suicidal thoughts and behaviors [see Warnings and Precautions (5.1)] Serotonin syndrome [see Warnings and Precautions (5.2)] Increased risk of bleeding [see Warnings and Precautions (5.5)] Activation of mania/hypomania [see Warnings and Precautions (5.6)] Discontinuation syndrome [see Warnings and Precautions (5.7)] Seizures [see Warnings and Precautions (5.8)] Angle-closure glaucoma [see Warnings and Precautions (5.9)] Hyponatremia [see Warnings and Precautions (5.10)] Sexual Dysfunction [see Warnings and Precautions (5.11)] Fracture [see Warnings and Precautions (5.12)] Most common adverse reactions (≥5% and at least twice placebo) are abnormal ejaculation,, asthenia, constipation, decreased appetite, diarrhea, dizziness, dry mouth, female genital disorder, impotence, infection, insomnia, libido decreased, male genital disorder, nausea, nervousness, somnolence, sweating, tremor, yawn. (6) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data for PAXIL are from: 6 six‑week clinical trials in adult patients with MDD.

Patients in the PAXIL group received PAXIL 20 mg to 50 mg once daily (Studies MDD-1, MDD-2, MDD-3, MDD-4, MDD-5, and MDD-6) [see Clinical Studies (14.1)]. 2 twelve-week clinical trials in adult patients with OCD. Patients in the PAXIL group received PAXIL 20 mg to 60 mg once daily (Studies OCD-1 and OCD-2) [see Clinical Studies (14.2)]. 3 ten to twelve‑week clinical trials in adult patients with PD.

Patients in the PAXIL group received PAXIL 10 mg to 60 mg once daily (Studies PD-1, PD-2, and PD-3) [see Clinical Studies (14.3)]. 3 twelve-week clinical trials in adult patients with SAD. Patients in the PAXIL group received PAXIL 20 mg to 50 mg once daily (Studies SAD-1, SAD-2, and SAD-3) [see Clinical Studies (14.4)]. 3 eight‑week clinical trials in adult patients with GAD.

Patients in the PAXIL group received PAXIL 10 mg to 50 mg once daily (Studies GAD-1, GAD-2, and GAD-3) [see Clinical Studies (14.5)]. 2 twelve‑week clinical trials in adult patients with PTSD. Patients in the PAXIL group received PAXIL 20 mg to 50 mg once daily (Studies PTSD -1 and PTSD -2) [see Clinical Studies (14.6)].

Adverse Reactions Leading to Discontinuation In clinical studies in adults with MDD, SAD, OCD, PD, GAD, and PTSD, 20% (1,199/6,145), 16% (84/522), 12% (64/542), 9% (44/469), 11% (79/735), and 12% (79/676) of PAXIL-treated patients, respectively, discontinued treatment due to an adverse reaction. The most common adverse reactions (³1%) associated with discontinuation (i.e., those adverse reactions associated with dropout at a rate approximately twice or greater for the PAXIL group compared to the placebo group) are presented in Table 3.

Table 3: Adverse Reactions That Led to Discontinuation (≥1% of PAXIL-Treated Patients and Greater than Placebo) in MDD, OCD, PD, SAD, GAD, and PTSD Adult Studies MDD OCD PD SAD GAD PTSD PAXIL Placebo PAXIL Placebo PAXIL Placebo PAXIL Placebo PAXIL Placebo PAXIL Placebo CNS Adverse Reactions Somnolence 2.3% 0.7% --- 1.9% 0.3% 3.4% 0.3% 2% 0.2% 2.8% 0.6% Insomnia --- --- 1.7% 0% 1.3% 0.3% 3.1% 0% --- --- Agitation 1.1% 0.5% --- --- --- Tremor 1.1% 0.3% --- 1.7% 0% 1% 0.2% Anxiety --- --- --- 1.1% 0% --- --- Dizziness --- --- 1.5% 0% 1.9% 0% 1% 0.2% --- --- Gastrointestinal Adverse Reactions Constipation --- 1.1% 0% --- --- Nausea 3.2% 1.1% 1.9% 0% 3.2% 1.2% 4% 0.3% 2% 0.2% 2.2% 0.6% Diarrhea 1% 0.3% --- Dry mouth 1% 0.3% --- --- --- Vomiting 1% 0.3% --- 1% 0% --- --- Flatulence 1% 0.3% --- --- Other Adverse Reactions Asthenia 1.6% 0.4% 1.9% 0.4% 2.5% 0.6% 1.8% 0.2% 1.6% 0.2% Abnormal Ejaculation a 1.6% 0% 2.1% 0% 4.9% 0.6% 2.5% 0.5% --- --- Sweating 1% 0.3% --- 1.1% 0% 1.1% 0.2% --- --- Impotence a --- 1.5% 0% --- --- Libido Decreased 1% 0% --- --- If numbers are not provided in the table, the incidence of the adverse reactions in PAXIL-treated patients was not >1% or was not ≥ 2 times the incidence in placebo-treated patients. a. Incidence corrected for sex.

Most Common Adverse Reactions The most commonly observed adverse reactions associated with the use of PAXIL (incidence of 5% or greater and at least twice that for placebo) were: MDD: Asthenia, sweating, nausea, decreased appetite, somnolence, dizziness, insomnia, tremor, nervousness, ejaculatory disturbance, and other male genital disorders. OCD: Nausea, dry mouth, decreased appetite, constipation, dizziness, somnolence, tremor, sweating, impotence, and abnormal ejaculation.

PD: Asthenia, sweating, decreased appetite, libido decreased, tremor, abnormal ejaculation, female genital disorders, and impotence. SAD: Sweating, nausea, dry mouth, constipation, decreased appetite, somnolence, tremor, libido decreased, yawn, abnormal ejaculation, female genital disorders, and impotence. GAD: Asthenia, infection, constipation, decreased appetite, dry mouth, nausea, libido decreased, somnolence, tremor, sweating, and abnormal ejaculation.

PTSD: Asthenia, sweating, nausea, dry mouth, diarrhea, decreased appetite, somnolence, libido decreased, abnormal ejaculation, female genital disorders, and impotence. Adverse Reactions in Adult Patients with MDD Table 4 presents the adverse reactions that occurred at an incidence of 1% or more and greater in the PAXIL group than the placebo group in clinical trials in adult patients with MDD (Studies MDD-1, MDD-2, MDD-3, MDD-4, MDD-5, and MDD-6).

Table 4: Adverse Reactions (≥1% of PAXIL-Treated Patients and Greater than Placebo Treated Patients) in 6-Week Clinical Trials od Adults with MDD PAXIL (n = 421) Placebo (n = 421) Nausea 26% 9% Somnolence 23% 9% Dry Mouth 18% 12% Headache 18% 17% Asthenia 15% 6% Constipation 14% 9% Ejaculatory Disyurbance a 13% 0% Dizziness 13% 6% Insomnia 13% 6% Diarrhea 12% 8% Sweating 11% 2% Other Male Genital Disorders b 10% 0% Tremor 8% 2% Decreased Appetite 6% 2% Nervousness 5% 3% Anxiety 5% 3% Yawn 4% 0% Blurred Vision 4% 1% Flatulence 4% 2% Paresthesia 4% 2% Palpitation 3% 1% Vasodilation 3% 1% Libido Decreased 3% 0% Urination Disorder d 3% 0% Urinary Frequency 3% 1% Taste Perversion 2% 0% Female Genital Disorders d 2% 0% Oropharynx Disorder e 2% 0% Myopathy 2% 1% Dyspepsia 2% 1% Rash 2% 1% Drugged Feeling 2% 1% Myalgia 2% 1% Confusion 1% 0% Myasthenia 1% 0% a. Ejaculatory disturbance mostly “ejaculatory delay.” b.

Other male genital disorders percentage corrected for sex. Includes “anorgasmia,” “erectile difficulties,” “delayed ejaculation/orgasm,” and “sexual dysfunction,” and “impotence.” c. Urination Disorder Includes mostly “difficulty with micturition” and “urinary hesitancy.” d. Female Genital Disorders includes mostly “anorgasmia” and “difficulty reaching climax/orgasm.” e.Oropharynx disorder includes mostly “lump in throat” and “tightness in throat.” Dose dependent adverse reactions in fixed‑dose studies (Study MDD-1, MDD-2, MDD-3, MDD-4, MDD-5, and MDD-6) for the treatment of adults with MDD that compared PAXIL10 mg, 20 mg, 30 mg, and 40 mg once daily with placebo once daily are shown in Table 5.

Table 5. Adverse Reactions (≥5% of PAXIL-Treated Patients and ≥ Twice the Rate of Placebo-Treated Patients) in a Study of Adults with MDD (Study MDD-1, MDD-2, MDD-3, MDD-4, MDD-5, and MDD-6) Placebo (n = 51) PAXIL 10 mg/day (n=102) 20 mg/day (n=104) 30 mg/day (n=101) 40 mg/day (n=102) Nausea 14% 15% 27% 35% 36% Somnolence 8% 13% 18% 21% 22% Dry Mouth 2% 11% 18% 16% 21% Diarrhea 8% 10% 19% 8% 15% Tremor 8% 0% 8% 8% 15% Asthenia 0% 3% 11% 14% 13% Abnormal Ejaculation 0% 6% 7% 11% 13% Constipation 6% 5% 8% 10% 13% Dizziness 4% 7% 8% 9% 13% Sweating 2% 1% 7% 9% 12% Blurred Vision 2% 3% 3% 2% 8% Anxiety 0% 2% 6% 6% 6% Paresthesia 0% 3% 1% 5% 6% Decreased Appetite 2% 2% 6% 4% 5% Male Genital Disorders 0% 4% 9% 6% 4% Nervousness 0% 6% 6% 4% 3% Impotence 0% 2% 4% 6% 2% Adverse Reactions in Adult Patients with OCD, PD, and SAD Table 6 presents adverse reactions that occurred at a frequency of 2% or more in clinical trials in adult patients with OCD, PD, and SAD (i.e., Studies OCD-1, OCD-2, PD-1, PD-2, PD-3, SAD-1, SAD-2, and SAD-3).

Dose -related adverse reactions in a 10-week fixed-dose study (Study PD-1) that compared placebo and PAXIL 10 mg, 20 mg, and 40 mg once daily in the treatment of adults with PD were asthenia, dry mouth, anxiety, libido decreased, tremor, and abnormal ejaculation. There was no clear relationship between adverse reactions and the PAXIL dosage in a: Fixed dose study (Study OCD-1) that compared placebo and PAXIL 20 mg, 40 mg, and 60 mg once daily in the treatment of adults with OCD Fixed dose study (SAD-3) that compared placebo and PAXIL 20 mg, 40 mg and 60 mg once daily in the treatment of adults with SAD.

Table 6. Adverse Reactions (≥2% of PAXIL-Treated Patients and Greater than Placebo- Treated Patients) in 10 to 12-Week Clinical Trials for OCD, PD, and SAD OCD PD SAD PAXIL (n = 542) Placebo (n = 265) PAXIL (n = 469) Placebo (n = 324) PAXIL (n = 425) Placebo (n = 339) Somnolence 24% 7% 19% 11% 22% 5% Insomnia 24% 13% 18% 10% 21% 16% Abnormal Ejaculation a 23% 1% 21% 1% 28% 1% Nausea 23% 10% 23% 17% 25% 7% Asthenia 22% 14% 14% 5% 22% 14% Dry Mouth 18% 9% 18% 11% 9% 3% Constipation 16% 6% 8% 5% 5% 2% Dizziness 12% 6% 14% 10% 11% 7% Tremor 11% 1% 9% 1% 9% 1% Diarrhea 10% 10% 12% 7% 9% 3% Sweating 9% 3% 14% 6% 9% 2% Decreased Appetite 9% 3% 7% 3% 8% 2% Nervousness 9% 8% --- --- 8% 7% Impotence a 8% 1% 5% 0% 5% 1% Decreased libido 7% 4% 9% 1% 12% 1% Abnormal Dreams 4% 1% --- --- --- --- Vasodilation 4% 1% ---- --- --- --- Abnormal Vision 4% 2% --- --- 4% 1% Increased Appetite 4% 3% 2% 1% 2% 1% Female Genital Disorder a 3% 0% 9% 1% 9% 1% Myoclonus 3% 0% 3% 2% 2% 1% Depersonalization 3% 0% --- --- --- --- Urination Impaired 3% 0% --- --- --- --- Concentration Impaired 3% 2% --- --- 4% 1% Chest Pain 3% 2% - - - - Rash 3% 2% --- --- --- --- Urinary Frequency 3% 1% 2% 0% --- --- Palpitation 2% 0% --- --- --- --- Taste Perversion 2% 0% --- --- --- --- Chills 2% 1% 2% 1% --- --- Urinary Tract Infection 2% 1% 2% 1% --- --- Amnesia 2% 1% - - - - Back Pain - - 3% 2% - - Agitation --- --- 5% 4% 3% 1% Anxiety --- --- 5% 4% 5% 4% Abdominal Pain - - 4% 3% --- --- Rhinitis - - 3% 0% - - Yawn - - - - 5% 1% Dysmenorrhea --- --- --- --- 5% 4% Dyspepsia - - - - 4% 2% Pharyngitis --- --- --- --- 4% 2% Myalgia --- --- --- --- 4% 3% Trauma --- --- --- --- 3% 1% Flatulence - - - - - 2% Vomiting - - - - 1% a.

Percentage corrected for sex. Adverse Reactions in Adult Patients with GAD and PTSD Table 7 presents adverse reactions that occurred at a frequency of 2% or more in clinical trials in adult patients with GAD and PTSD (i.e., Studies GAD-1, GAD-2, PTSD-1, and PTSD-2). Dose-related adverse reactions in a fixed dose studies that compared: Placebo and PAXIL 20 mg and 40 mg once daily in the treatment of adults with GAD were asthenia, constipation, and abnormal ejaculation.

Placebo and PAXIL 20 mg and 40 mg once daily in the treatment of adults with PTSD were impotence and abnormal ejaculation. Table 7. Adverse Reactions (≥2% of PAXIL-Treated Patients and Greater than Placebo) in 8- to 12-Week Clinical Trials for GAD and PTSD a Generalized Anxiety Disorder Posttraumatic Stress Disorder Paxil (n= 735) Placebo (n = 529) PAXIL (n = 676) Placebo (n = 504) Abnormal Ejaculation a 25% 2% 13% 2% Nausea 20% 5% 19% 8% Headache 17% 14% --- --- Somnolence 15% 5% 16% 5% Asthenia 14% 6% 12% 4% Dry Mouth 11% 5% 10% 5% Insomnia 9% 2% 5% 2% Constipation 10% 2% 5% 3% Libido Decreased 9% 2% 5% 3% Diarrhea 9% 7% 11% 5% Respiratory Disorder 7% 5% --- --- Sweating 6% 2% 5% 1% Infection 6% 3% 5% 4% Dizziness 6% 5% 6% 5% Decreased Appetite 5% 1% 6% 3% Tremor 5% 1% 4% 1% Female Genital Disorder a 4% 1% 5% 1% Yawn 4% --- 2% <1% Nervousness 4% 3% --- --- Sinusitis 4% 3% --- --- Impotence a 4% 3% 9% 1% Vasodilation 3% 1% 2% 1% Vomiting 3% 2% 3% 2% Abnormal Vision 2% 1% 3% 1% Trauma 6% 5% Dyspepsia --- --- 5% 3% Abdominal Pain 4% 3% Abnormal Dreams 3% a.

Percentage corrected for sex Male and Female Sexual Dysfunction The percentage of patients who reported symptoms of sexual dysfunction in males and females with MDD, OCD, PD, SAD, GAD, and PTSD (i.e., Studies MDD-1, MDD-2, MDD-3, MDD-4, MDD-5, and MDD-6; OCD-1 and OCD-2; PD-1, PD-2, and PD-3; SAD-1, SAD-2, and SAD-3; GAD-1 and GAD-2; PTSD-1 and PTSD-2) are displayed in Table 8. Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, however, in part because patients and healthcare providers may be reluctant to discuss them.

Accordingly, estimates of the incidence of untoward sexual experience and performance cited in labeling may underestimate their actual incidence. PAXIL treatment has been associated with several cases of priapism. In those cases, with a known outcome, patients recovered without sequelae. Table 8. Adverse Reactions Related to Sexual Dysfunction in Clinical Trials of Adults with MDD, OCD, PD, SAD, GAD, and PTSD Males PAXIL (n=1446) Placebo (n=1042) Decreased Libido 6% to 15% 0% to 5% Ejaculatory Disturbance 13% to 28% 0% to 2% Impotence 2% to 9% 0% to 3% Females PAXIL (n=1,822) Placebo (n=1,340) Decreased Libido 0% to 9% 0% to 2% Orgasmic Disturbance 2% to 9% 0% to 1% Hallucinations In pooled clinical trials of PAXIL, hallucinations were observed in 0.2% of PAXIL-treated patients compared to 0.1% of placebo-treated patients.

Less Common Adverse Reactions The following adverse reactions occurred during the clinical studies of PAXIL and are not included elsewhere in the labeling. Adverse reactions are categorized by body system and listed in order of decreasing frequency according to the following definitions: Frequent adverse reactions are those that occurred on 1 or more occasion in at least 1/100 patients.

Infrequent adverse reactions are those that occurred in 1/100 to 1/1,000 patients Rare adverse reactions are those that occurred in fewer than 1/1,000 patients. Body as a Whole Infrequent: Allergic reaction, chills, face edema, malaise, neck pain; rare: Adrenergic syndrome, cellulitis, moniliasis, neck rigidity, pelvic pain, peritonitis, sepsis, ulcer.

Cardiovascular System Frequent: Hypertension, tachycardia; infrequent: Bradycardia, hematoma, hypotension, migraine, postural hypotension, syncope; rare: Angina pectoris, arrhythmia nodal, atrial fibrillation, bundle branch block, cerebral ischemia, cerebrovascular accident, congestive heart failure, heart block, low cardiac output, myocardial infarct, myocardial ischemia, pallor, phlebitis, pulmonary embolus, supraventricular extrasystoles, thrombophlebitis, thrombosis, varicose vein, vascular headache, ventricular extrasystoles. Digestive System Infrequent: Bruxism, colitis, dysphagia, eructation, gastritis, gastroenteritis, gingivitis, glossitis, increased salivation, abnormal liver function tests, rectal hemorrhage, ulcerative stomatitis; rare: Aphthous stomatitis, bloody diarrhea, bulimia, cardiospasm, cholelithiasis, duodenitis, enteritis, esophagitis, fecal impactions, fecal incontinence, gum hemorrhage, hematemesis, hepatitis, ileitis, ileus, intestinal obstruction, jaundice, melena, mouth ulceration, peptic ulcer, salivary gland enlargement, sialadenitis, stomach ulcer, stomatitis, tongue discoloration, tongue edema, tooth caries.

Endocrine System Rare: Diabetes mellitus, goiter, hyperthyroidism, hypothyroidism, thyroiditis. Hemic and Lymphatic Systems Infrequent: Anemia, leukopenia, lymphadenopathy, purpura; rare: Abnormal erythrocytes, basophilia, bleeding time increased, eosinophilia, hypochromic anemia, iron deficiency anemia, leukocytosis, lymphedema, abnormal lymphocytes, lymphocytosis, microcytic anemia, monocytosis, normocytic anemia, thrombocythemia, thrombocytopenia.

Metabolic and Nutritional Frequent: Weight gain; infrequent: Edema, peripheral edema, SGOT increased, SGPT increased, thirst, weight loss; rare: Alkaline phosphatase increased, bilirubinemia, BUN increased, creatinine phosphokinase increased, dehydration, gamma globulins increased, gout, hypercalcemia, hypercholesteremia, hyperglycemia, hyperkalemia, hyperphosphatemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, ketosis, lactic dehydrogenase increased, non‑protein nitrogen (NPN) increased. Musculoskeletal System Frequent: Arthralgia; infrequent: Arthritis, arthrosis; rare: Bursitis, myositis, osteoporosis, generalized spasm, tenosynovitis, tetany.

Nervous System Frequent: Emotional lability, vertigo; infrequent: Abnormal thinking, alcohol abuse, ataxia, dystonia, dyskinesia, euphoria, hostility, hypertonia, hypesthesia, hypokinesia, incoordination, lack of emotion, libido increased, manic reaction, neurosis, paralysis, paranoid reaction; rare: Abnormal gait, akinesia, antisocial reaction, aphasia, choreoathetosis, circumoral paresthesias, convulsion, delirium, delusions, diplopia, drug dependence, dysarthria, extrapyramidal syndrome, fasciculations, grand mal convulsion, hyperalgesia, hysteria, manic-depressive reaction, meningitis, myelitis, neuralgia, neuropathy, nystagmus, peripheral neuritis, psychotic depression, psychosis, reflexes decreased, reflexes increased, stupor, torticollis, trismus, withdrawal syndrome. Respiratory System Infrequent: Asthma, bronchitis, dyspnea, epistaxis, hyperventilation, pneumonia, respiratory flu; rare: Emphysema, hemoptysis, hiccups, lung fibrosis, pulmonary edema, sputum increased, stridor, voice alteration.

Skin and Appendages Frequent: Pruritus; infrequent: Acne, alopecia, contact dermatitis, dry skin, ecchymosis, eczema, herpes simplex, photosensitivity, urticaria; rare: Angioedema, erythema nodosum, erythema multiforme, exfoliative dermatitis, fungal dermatitis, furunculosis; herpes zoster, hirsutism, maculopapular rash, seborrhea, skin discoloration, skin hypertrophy, skin ulcer, sweating decreased, vesiculobullous rash. Special Senses Frequent: Tinnitus; infrequent: Abnormality of accommodation, conjunctivitis, ear pain, eye pain, keratoconjunctivitis, mydriasis, otitis media; rare: Amblyopia, anisocoria, blepharitis, cataract, conjunctival edema, corneal ulcer, deafness, exophthalmos, eye hemorrhage, glaucoma, hyperacusis, night blindness, otitis externa, parosmia, photophobia, ptosis, retinal hemorrhage, taste loss, visual field defect.

Urogenital System Infrequent: Amenorrhea, breast pain, cystitis, dysuria, hematuria, menorrhagia, nocturia, polyuria, pyuria, urinary incontinence, urinary retention, urinary urgency, vaginitis; rare: Abortion, breast atrophy, breast enlargement, endometrial disorder, epididymitis, female lactation, fibrocystic breast, kidney calculus, kidney pain, leukorrhea, mastitis, metrorrhagia, nephritis, oliguria, salpingitis, urethritis, urinary casts, uterine spasm, urolith, vaginal hemorrhage, vaginal moniliasis.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following reactions have been identified during post approval use of paroxetine. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood system disorders: events related to impaired hematopoiesis (including agranulocytosis, aplastic anemia, bone marrow aplasia and pancytopenia), hemolytic anemia Cardiac disorders: torsade de pointes, ventricular fibrillation, ventricular tachycardia Endocrine disorders: hyperprolactinemia, syndrome of inappropriate antidiuretic hormone (SIADH) secretion Gastrointestinal disorders: acute pancreatitis Hepatobiliary disorders: elevated liver function tests (the most severe cases were deaths due to liver necrosis, and grossly elevated transaminases associated with severe liver dysfunction) Immune system disorders: anaphylactic reaction, vasculitis syndromes (such as Henoch-Schönlein purpura).

Metabolism and nutrition disorders: porphyria Musculoskeletal and connective tissue disorders: Hypertonia Nervous system disorders: extrapyramidal symptoms (i.e. akathisia, bradykinesia, cogwheel rigidity, oculogyric crisis which has been associated with concomitant use of pimozide), Guillain-Barré Syndrome, anosmia, hyposmia, optic neuritis, restless legs syndrome (RLS), status epilepticus Pregnancy, puerperium and perinatal conditions: eclampsia, premature birth Renal disorders: acute renal failure Reproductive system and breast disorders: galactorrhea, priapism Respiratory, disorders: allergic alveolitis, laryngospasm, pulmonary hypertension Skin and subcutaneous tissue disorders: Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN) Vascular disorders: severe hypotension

Adverse reaction frequency tables (US label) US FDA label
MDD OCD PD SAD GAD PTSD
PAXIL Placebo PAXIL Placebo PAXIL Placebo PAXIL Placebo PAXIL Placebo PAXIL Placebo
CNS Adverse Reactions
Somnolence 2.3% 0.7% --- 1.9% 0.3% 3.4% 0.3% 2% 0.2% 2.8% 0.6%
Insomnia --- --- 1.7% 0% 1.3% 0.3% 3.1% 0% --- ---
Agitation 1.1% 0.5% --- --- ---
Tremor 1.1% 0.3% --- 1.7% 0% 1% 0.2%
Anxiety --- --- --- 1.1% 0% --- ---
Dizziness --- --- 1.5% 0% 1.9% 0% 1% 0.2% --- ---
Gastrointestinal Adverse Reactions
Constipation --- 1.1% 0% --- ---
Nausea 3.2% 1.1% 1.9% 0% 3.2% 1.2% 4% 0.3% 2% 0.2% 2.2% 0.6%
Diarrhea 1% 0.3% ---
Dry mouth 1% 0.3% --- --- ---
Vomiting 1% 0.3% --- 1% 0% --- ---
Flatulence 1% 0.3% --- ---
Other Adverse Reactions
Asthenia 1.6% 0.4% 1.9% 0.4% 2.5% 0.6% 1.8% 0.2% 1.6% 0.2%
Abnormal Ejaculationa 1.6% 0% 2.1% 0% 4.9% 0.6% 2.5% 0.5% --- ---
Sweating 1% 0.3% --- 1.1% 0% 1.1% 0.2% --- ---
Impotencea --- 1.5% 0% --- ---
Libido Decreased 1% 0% --- ---
PAXIL (n = 421) Placebo (n = 421)
Nausea 26% 9%
Somnolence 23% 9%
Dry Mouth 18% 12%
Headache 18% 17%
Asthenia 15% 6%
Constipation 14% 9%
Ejaculatory Disyurbancea 13% 0%
Dizziness 13% 6%
Insomnia 13% 6%
Diarrhea 12% 8%
Sweating 11% 2%
Other Male Genital Disordersb 10% 0%
Tremor 8% 2%
Decreased Appetite 6% 2%
Nervousness 5% 3%
Anxiety 5% 3%
Yawn 4% 0%
Blurred Vision 4% 1%
Flatulence 4% 2%
Paresthesia 4% 2%
Palpitation 3% 1%
Vasodilation 3% 1%
Libido Decreased 3% 0%
Urination Disorderd 3% 0%
Urinary Frequency 3% 1%
Taste Perversion 2% 0%
Female Genital Disordersd 2% 0%
Oropharynx Disordere 2% 0%
Myopathy 2% 1%
Dyspepsia 2% 1%
Rash 2% 1%
Drugged Feeling 2% 1%
Myalgia 2% 1%
Confusion 1% 0%
Myasthenia 1% 0%
Placebo (n = 51) PAXIL
10 mg/day (n=102) 20 mg/day (n=104) 30 mg/day (n=101) 40 mg/day (n=102)
Nausea 14% 15% 27% 35% 36%
Somnolence 8% 13% 18% 21% 22%
Dry Mouth 2% 11% 18% 16% 21%
Diarrhea 8% 10% 19% 8% 15%
Tremor 8% 0% 8% 8% 15%
Asthenia 0% 3% 11% 14% 13%
Abnormal Ejaculation 0% 6% 7% 11% 13%
Constipation 6% 5% 8% 10% 13%
Dizziness 4% 7% 8% 9% 13%
Sweating 2% 1% 7% 9% 12%
Blurred Vision 2% 3% 3% 2% 8%
Anxiety 0% 2% 6% 6% 6%
Paresthesia 0% 3% 1% 5% 6%
Decreased Appetite 2% 2% 6% 4% 5%
Male Genital Disorders 0% 4% 9% 6% 4%
Nervousness 0% 6% 6% 4% 3%
Impotence 0% 2% 4% 6% 2%
OCD PD SAD
PAXIL (n = 542) Placebo (n = 265) PAXIL (n = 469) Placebo (n = 324) PAXIL (n = 425) Placebo (n = 339)
Somnolence 24% 7% 19% 11% 22% 5%
Insomnia 24% 13% 18% 10% 21% 16%
Abnormal Ejaculationa 23% 1% 21% 1% 28% 1%
Nausea 23% 10% 23% 17% 25% 7%
Asthenia 22% 14% 14% 5% 22% 14%
Dry Mouth 18% 9% 18% 11% 9% 3%
Constipation 16% 6% 8% 5% 5% 2%
Dizziness 12% 6% 14% 10% 11% 7%
Tremor 11% 1% 9% 1% 9% 1%
Diarrhea 10% 10% 12% 7% 9% 3%
Sweating 9% 3% 14% 6% 9% 2%
Decreased Appetite 9% 3% 7% 3% 8% 2%
Nervousness 9% 8% --- --- 8% 7%
Impotencea 8% 1% 5% 0% 5% 1%
Decreased libido 7% 4% 9% 1% 12% 1%
Abnormal Dreams 4% 1% --- --- --- ---
Vasodilation 4% 1% ---- --- --- ---
Abnormal Vision 4% 2% --- --- 4% 1%
Increased Appetite 4% 3% 2% 1% 2% 1%
Female Genital Disordera 3% 0% 9% 1% 9% 1%
Myoclonus 3% 0% 3% 2% 2% 1%
Depersonalization 3% 0% --- --- --- ---
Urination Impaired 3% 0% --- --- --- ---
Concentration Impaired 3% 2% --- --- 4% 1%
Chest Pain 3% 2% - - - -
Rash 3% 2% --- --- --- ---
Urinary Frequency 3% 1% 2% 0% --- ---
Palpitation 2% 0% --- --- --- ---
Taste Perversion 2% 0% --- --- --- ---
Chills 2% 1% 2% 1% --- ---
Urinary Tract Infection 2% 1% 2% 1% --- ---
Amnesia 2% 1% - - - -
Back Pain - - 3% 2% - -
Agitation --- --- 5% 4% 3% 1%
Anxiety --- --- 5% 4% 5% 4%
Abdominal Pain - - 4% 3% --- ---
Rhinitis - - 3% 0% - -
Yawn - - - - 5% 1%
Dysmenorrhea --- --- --- --- 5% 4%
Dyspepsia - - - - 4% 2%
Pharyngitis --- --- --- --- 4% 2%
Myalgia --- --- --- --- 4% 3%
Trauma --- --- --- --- 3% 1%
Flatulence - - - - - 2%
Vomiting - - - - 1%
Generalized Anxiety Disorder Posttraumatic Stress Disorder
Paxil (n= 735) Placebo (n = 529) PAXIL (n = 676) Placebo (n = 504)
Abnormal Ejaculationa 25% 2% 13% 2%
Nausea 20% 5% 19% 8%
Headache 17% 14% --- ---
Somnolence 15% 5% 16% 5%
Asthenia 14% 6% 12% 4%
Dry Mouth 11% 5% 10% 5%
Insomnia 9% 2% 5% 2%
Constipation 10% 2% 5% 3%
Libido Decreased 9% 2% 5% 3%
Diarrhea 9% 7% 11% 5%
Respiratory Disorder 7% 5% --- ---
Sweating 6% 2% 5% 1%
Infection 6% 3% 5% 4%
Dizziness 6% 5% 6% 5%
Decreased Appetite 5% 1% 6% 3%
Tremor 5% 1% 4% 1%
Female Genital Disordera 4% 1% 5% 1%
Yawn 4% --- 2% <1%
Nervousness 4% 3% --- ---
Sinusitis 4% 3% --- ---
Impotencea 4% 3% 9% 1%
Vasodilation 3% 1% 2% 1%
Vomiting 3% 2% 3% 2%
Abnormal Vision 2% 1% 3% 1%
Trauma 6% 5%
Dyspepsia --- --- 5% 3%
Abdominal Pain 4% 3%
Abnormal Dreams 3%
Males
PAXIL (n=1446) Placebo (n=1042)
Decreased Libido 6% to 15% 0% to 5%
Ejaculatory Disturbance 13% to 28% 0% to 2%
Impotence 2% to 9% 0% to 3%
Females
PAXIL (n=1,822) Placebo (n=1,340)
Decreased Libido 0% to 9% 0% to 2%
Orgasmic Disturbance 2% to 9% 0% to 1%

Pharmacokinetics

Half-life and elimination (verbatim, US label)

At steady state, mean values of C max , T max , C min , and T½ were 61.7 ng/mL (CV 45%), 5.2 hours (CV 10%), 30.7 ng/mL (CV 67%), and 21 hours (CV 32%), respectively.

Elimination Metabolism: The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg PAXIL tablets daily for 30 days.

Excretion: Approximately 64% of a 30-mg oral solution dose of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites over a 10‑day post‑dosing period.

About 36% was excreted in the feces (probably via the bile), mostly as metabolites and less than 1% as the parent compound over the 10‑day post‑dosing period.

Pharmacokinetics (US label) US FDA label

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of PAXIL in the treatment of major depressive disorder (MDD), social anxiety disorder (SAD), obsessive compulsive disorder (OCD), panic disorder (PD), generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD) is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5‑hydroxy‑tryptamine, 5‑HT). 12.2 Pharmacodynamics Studies at clinically relevant paroxetine dosage in humans have demonstrated that paroxetine blocks the uptake of serotonin into human platelets. In vitro studies in animals also suggest that paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake (SSRI) and has only very weak effects on norepinephrine and dopamine neuronal reuptake.

Cardiac Electrophysiology At the maximum recommended paroxetine dose, a mean increase in the QTc interval >20 milliseconds is unlikely. 12.3 Pharmacokinetics Nonlinearity in pharmacokinetics was observed with increasing dosage of PAXIL. In a meta-analysis of paroxetine from 4 studies done in healthy volunteers following multiple PAXIL dosing of 20 mg/day to 40 mg/day, males did not exhibit a significantly lower C max or AUC than females.

Absorption Paroxetine was completely absorbed after oral dosing of a paroxetine solution of the hydrochloride salt. In a study in which healthy male subjects (n = 15) received 30 mg PAXIL tablets daily for 30 days, steady‑state paroxetine concentrations were achieved by approximately 10 days for most subjects, although it took substantially longer in some subjects.

At steady state, mean values of C max, T max, C min, and T½ were 61.7 ng/mL (CV 45%), 5.2 hours (CV 10%), 30.7 ng/mL (CV 67%), and 21 hours (CV 32%), respectively. The steady‑state C max and C min values were about 6 and 14 times what would be predicted from single‑dose studies. Steady‑state drug exposure based on AUC 0-24 was about 8 times greater than would have been predicted from single-dose data in these subjects.

The excess accumulation is a consequence of the fact that one of the enzymes that metabolizes paroxetine is readily saturable. Paroxetine has similar exposure after administration of the tablets and oral suspension. Effect of Food: The effects of food on the bioavailability of paroxetine were studied in subjects who received a single PAXIL dose with and without food.

AUC was slightly increased (6%) when PAXIL was administered with food but the C max was 29% greater, while the time to reach peak plasma concentration decreased from 6.4 hours post‑dosing to 4.9 hours [see Dosage and Administration (2.1)]. Distribution Paroxetine distributes throughout the body, including the CNS, with only 1% remaining in the plasma.

Approximately 95% and 93% of paroxetine is bound to plasma protein at 100 ng/mL and 400 ng/mL, respectively. Under clinical conditions, paroxetine concentrations would normally be less than 400 ng/mL. Paroxetine does not alter the in vitro protein binding of phenytoin or warfarin. Elimination Metabolism: The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg PAXIL tablets daily for 30 days.

In steady‑state dose proportionality studies involving elderly and nonelderly patients, at PAXIL doses of 20 mg to 40 mg daily for the elderly and 20 mg to 50 mg daily for the nonelderly, some nonlinearity was observed in both populations, again reflecting a saturable metabolic pathway. In comparison to C min values after 20 mg of PAXIL daily, values after 40 mg of PAXIL daily were only about 2 to 3 times greater than doubled.

Paroxetine is extensively metabolized after oral PAXIL administration. The principal metabolites are polar and conjugated products of oxidation and methylation, which are readily cleared. Conjugates with glucuronic acid and sulfate predominate, and major metabolites have been isolated and identified. Data indicate that the metabolites have no more than 1/50 the potency of the parent compound at inhibiting serotonin uptake.

The metabolism of paroxetine is accomplished in part by CYP2D6. Saturation of CYP2D6 at clinical doses appears to account for the nonlinearity of paroxetine kinetics with increasing dose and increasing duration of treatment. The role of CYP2D6 in paroxetine metabolism increases the risk of drug interactions [see Drug Interactions (7)].

Pharmacokinetic characteristics of paroxetine has not been evaluated in subjects who are deficient in CYP2D6 (CYP2D6 poor metabolizers). Excretion: Approximately 64% of a 30-mg oral solution dose of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites over a 10‑day post‑dosing period.

About 36% was excreted in the feces (probably via the bile), mostly as metabolites and less than 1% as the parent compound over the 10‑day post‑dosing period. Drug Interaction Studies There are clinically significant, known drug interactions between PAXIL and other drugs [see Drug Interactions (7)]. See Figure 1 for the impact of paroxetine on the pharmacokinetics of concomitantly administered drugs and Figure 2 for the impact of other drugs on paroxetine pharmacokinetics.

Figure 1. Impact of Paroxetine on the Pharmacokinetics of Co-Administered Drugs (log scale) Pimozide is a 3A4 moderate sensitive substrate and is a CYP2D6 substrate; desipramine is a 2D6 sensitive substrate; propranolol is a 2D6 moderate sensitive substrate, digoxin is P-gp substrate, and phenytoin is a 3A4 strong inhibitor.

Figure 2. Impact of Concomitantly Administered Drugs on the Pharmacokinetics of Paroxetine Cimetidine is a OCT2, MATE1, and MATE2-K inhibitor, phenobarbital is a 3A4 moderate inducer, phenytoin is a 3A4 strong inhibitor, digoxin is P-gp substrate, and diazepam is a 2C19 moderate sensitive substrate. The increased paroxetine exposure after concomitant use of PAXIL with cimetidine is not expected to be clinically significant.

Theophylline: Reports of elevated theophylline levels associated with PAXIL treatment have been reported Drugs Metabolized by Cytochrome CYP3A4: An in vivo interaction study involving the concomitant use of steady-state paroxetine and a substrate for CYP3A4, revealed no effect of paroxetine on pharmacokinetics of the CYP3A4 substrate. In addition, in vitro studies have shown ketoconazole, a severe CYP3A4 inhibitor activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for CYP3A4, including triazolam and cyclosporine.

Paroxetine’s extent of CYP3A4 inhibition is not expected to be of clinical significance. Specific Populations The impact of specific populations on the pharmacokinetics of paroxetine are shown in Figure 3. Although the AUC and Cmax was higher in patients with mild renal impairment (RI) or moderate RI compared to those without RI, there was a lot of variability in the exposure and the clinical significance of these findings are unknown [see Use in Specific Populations (8.6)].

For recommendations for use of PAXIL in geriatric patients, patients with severe hepatic impairment, or severe hepatic impairment, see Use in Specific Populations (8.5, 8.6, and 8.7), respectively. Figure 3. Impact of Specific Population on the Pharmacokinetics of Paroxetine (log scale)

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. PAXIL · Apotex Corp [US FDA-approved label, version 13, September 29, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .